Retatrutide will likely cost slightly more at launch given its added complexity, but manufacturer savings programs could bring both to similar out-of-pocket costs for eligible patients
TRIUMPH-2 focuses on type 2 diabetes, comparing retatrutide against placebo and an active comparator in a population where glycemic control is the primary endpoint alongside weight
Does retatrutide reduce dopamine reward?Advanced GLP-1 science suggests these drugs modulate dopamine in the brains reward center to stop food noise, which may inadvertently affect other reward-seeking behaviors
Scientific references TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial (NEJM, 2023) Retatrutide for people with type 2 diabetes a Phase 2 trial (The Lancet, 2023) LY3437943 (retatrutide), a triple GIP/GLP-1/glucagon agonist Phase 1b trial MHRA: avoid illegal online weight-loss medicines MHRA Drug Safety Update: GLP-1 / GIP agonists pancreatitis warnings NICE TA875: Semaglutide for overweight and obesity NICE TA1026: Tirzepatide for overweight and obesity Incretin-based drugs and gallbladder / biliary disease (The Lancet) Final word for UK research customers A retatrutide 40mg pen is a pre-filled, ready-to-use research peptide with 40mg in the tank roughly 240 clicks, enough for many small doses or a handful of big ones
Once-Weekly Semaglutide in Adults with Overweight or Obesity, The New England Journal of Medicine, John P.H
